In this pre-treated advanced HNSCC population, PD-L1/PD-1 signalling pathway inhibition by atezolizumab had a tolerable safety profile and encouraging activity, with responses observed regardless of HPV status and PD-L1 expression level. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.